Welcome to ABDO Myopia Management Updates, a whistle-stop tour of the research, articles, comment and information that has been circulating in the world of myopia.
We aim to pick out the information of interest to DOs and build on the foundation information in the Clinical Hub.
We are always interested in new content that you think should be more widely known and information that you have found useful – please do send links across.
Feedback is of course always welcome.
ABDO Clinical Lead April 2021
On Tuesday, April 13, The Economist is hosting a virtual event – Reshaping the Future of Myopia: Addressing a Global Epidemic. The session, sponsored by Johnson & Johnson Vision, will bring together leaders in the eye care field and public health officials with the goal of spreading awareness on the growing prevalence of myopia as a global health concern. Read more and register for the event here.
Although, as previously mentioned, the research on combination strategies in myopia management is sparse and limited mainly to atropine with ortho-K, this short article touches on the latest thinking and references an ongoing atropine and soft contact lens research project as well as a randomised trail written up in Scientific Reports, 2020.
Members who have looked at the content on ABDO’s Myopia Management pages may have noticed that we often have to move between outcomes expressed in percentages, dioptres, and axial length measurements in mm. All the content is based on the myopia management pages is based on peer reviewed research papers, which ensures the information is robust and unbiased, however these papers can express the outcomes of their research in different ways. An important part of the role of the DO of the future will be the analysis of data – you may already see manufacturers’ brochures written with the best possible spin! For example, when talking about high index lenses, doesn’t “15% reduction in lens thickness” does sound more appealing than “reduces edge thickness by 0.5mm”? Therefore it was interesting to come across a paper which addresses this issue and makes some interesting recommendations. Published by Brennan, Toubouti, Cheng and Bullimore it is available to read under an open access agreement here. It recommends that axial length should be the preferred metric for monitoring progression, “cumulative absolute reduction in axial elongation” (CARE) , and goes on to discuss how early effects may not be a reliable indicator of longer term outcomes.
Following on from one of our previous updates where colleagues pondered on cases where axial length and the level of myopia didn’t correlate there is now an Axial length in Myopia Control webinar available to watch on demand. Presented by Thomas Aller, it covers Why measure, How to measure, What does it mean. The webinar is sponsored by Haag-Streit USA.
Although not presently available in the UK it is always interesting to hear of the latest research coming out in the field of atropine use. We cover atropine in the Clinical Hub Myopia Management section on pharmacological approaches. Here are more details of a three year study by Thao Ha at the Hai Yen Vision Institute which is further evidence that children can benefit from low dose atropine treatment.
Many of us are puzzled by the relationship between axial length and myopia- or more precisely when the two just don’t seem to coincide.
This short, interesting article produced with the support of Oculus and published by Myopia Profile explains the process of emmetropization and where, without the benefit of axial length measurement, the eye care practitioner can be fooled!
The International Myopia Institute (IMI) is the go to place for scholarly articles and information on myopia management and in conjunction with the European Society of Ophthalmology (SOE) has been working to promote the issue of myopia as a debilitating ocular condition. We talk in the ABDO Clinical Hub Myopia Management section of the other pandemic that is quietly going on – the prevalence of myopia in Europe alone is expected to grow from 2.6 billion people in 2020 to 4.9 billion in 2050 and myopia is predicted to become the most common cause of irreversible vison impairment and blindness worldwide.
New European guidance has been published to update everyone on this critical public health issue which you can read here.
ABDO does not endorse nor recommend one approach to myopia management above another nor does it have any recommendations on appropriate products. The information on these pages is to facilitate practitioners’ ability to have an informed discussion with patients and their parents/carers, and signpost practitioners who do wish to research the subject in more depth.